Oclacitinib for the Treatment of Nasal Alar Arteriopathy in Two Dogs
Katherine Bingham, Mara Kraenzlin, Dianne Kittrell, Beth Whitney, Andrew McGlinchey, Nina Shoulberg · 2026
Read Oclacitinib for the Treatment of Nasal Alar Arteriopathy in Two Dogs by Katherine Bingham, Mara Kraenzlin, Dianne Kittrell, Beth Whitney, Andrew McGlinchey, Nina Shoulberg (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13295816.txt.
Description
Katherine Bingham and colleagues report the first use of oclacitinib alone for a rare nose condition in dogs, in a 2026 report. Nasal alar arteriopathy scars and ulcerates the fold at the dog's nostril and can bleed hard. Care is often surgery, ointments, or immune-damping drugs. Two dogs were treated with oclacitinib, a drug known from itchy skin disease.
Both dogs improved a great deal on the drug alone. Gains in this condition can be hard to win, and relapse is common, so a single gentle drug is welcome news. The drug is well tolerated, with rare body-wide side effects. The authors offer it as an option for dogs that cannot take the standard immune-damping drugs or skin treatments.
Catalog record
| CREATOR | Katherine Bingham, Mara Kraenzlin, Dianne Kittrell, Beth Whitney, Andrew McGlinchey, Nina Shoulberg |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |